Crospovidone XL-10 is a crosslinked, water-insoluble form of polyvinylpyrrolidone, commonly used as a pharmaceutical superdisintegrant. I use the term “XL-10” carefully because grade names can be supplier-specific; the exact particle-size distribution, moisture content, and other specifications should always be confirmed in the current technical data sheet and certificate of analysis. In tablet development, the material is selected mainly to help a compressed dosage form break apart rapidly when it contacts an aqueous medium.
Click here to get more.
For an initial formulation screen, I would typically evaluate crospovidone at approximately 2–5% w/w, while recognizing that the appropriate level depends on the active ingredient, tablet structure, compression conditions, and target disintegration performance. A 100 mg tablet containing 2–5% crospovidone would therefore contain approximately 2–5 mg of the excipient. These values are development starting points rather than universal product specifications or guaranteed performance results.
Crospovidone works primarily through rapid liquid uptake and swelling or deformation within the tablet matrix. Unlike some water-soluble binders, it does not dissolve to form a viscous gel under normal tablet-disintegration conditions. This can help water penetrate the compact and promote tablet breakup, although the final result is influenced by the complete formulation and manufacturing process.
The practical value of crospovidone is not determined by the excipient alone. Particle size, surface area, grade consistency, blending order, lubricant concentration, and compression pressure can all affect performance. I therefore recommend treating crospovidone XL-10 as one part of a system rather than assuming that increasing the level will automatically produce faster disintegration.
The most common application is immediate-release tablet development. Crospovidone may be incorporated through direct compression, wet granulation, or dry granulation, depending on the powder characteristics and process design. It can be placed intragranularly, extragranularly, or divided between both locations, but the best approach should be established through comparative trials.
Extragranular addition may help the disintegrant remain available near the tablet surface and between granules. Intragranular addition may provide a different distribution within the granule structure. I would compare these approaches using measurable tests such as disintegration time, dissolution, hardness, friability, and content uniformity rather than relying only on excipient name or grade.
Crospovidone can also be considered in hard capsules when rapid dispersion of the fill material is required. Its role may be particularly relevant when the blend contains poorly wettable ingredients or when the capsule contents form a compact mass after contact with liquid. The final outcome still depends on fill density, shell behavior, powder wettability, and the release requirements of the product.
In orally disintegrating dosage forms, the balance between mechanical strength, mouthfeel, porosity, and rapid breakup becomes more demanding. Crospovidone may support rapid liquid access, but it is not a complete solution for taste masking, tablet robustness, or sensory performance. I recommend evaluating the grade with the actual active ingredient and excipient matrix intended for commercial manufacture.
Commercial crospovidone grades may differ in particle-size distribution, morphology, moisture profile, bulk density, and processing behavior. A designation such as “XL-10” may indicate a particular fine-particle or performance category within a supplier’s product family, but the name alone does not provide enough information for a reliable technical comparison. Buyers should request the current specification, typical values, regulatory documentation, and change-control information before approving a grade.
Particle size can influence blend uniformity, flow, compactability, and disintegration behavior. Finer material may disperse differently from a coarser grade, while a coarser grade may show different handling characteristics in a high-speed tableting process. I would avoid selecting a grade solely because its name resembles another supplier’s product; an application trial and specification comparison are more dependable.
Goto Yuking to know more.
| Evaluation area | Why it matters | What I recommend checking |
|---|---|---|
| Particle-size profile | May affect flow, mixing, compaction, and liquid penetration | Specification limits, typical distribution, and test method |
| Moisture or loss on drying | Can influence processing and product stability | Release limits, storage guidance, and packaging |
| Microbiological quality | Relevant to pharmaceutical manufacturing controls | Applicable limits and batch documentation |
| Batch consistency | Supports reproducible formulation and process performance | CoA review, retained samples, and change notification policy |
A practical screening plan may compare several crospovidone levels around the 2–5% w/w range, along with different addition locations. The optimum level is usually the lowest concentration that meets the product’s disintegration and dissolution requirements without creating unacceptable effects on hardness, friability, flow, or tablet weight. If the active ingredient is sensitive to moisture or the formulation is highly soluble, the screening range may need to be adjusted.
Excessive compression can create a dense tablet that resists liquid penetration, even when an effective superdisintegrant is present. Over-lubrication may also reduce wettability or alter interparticle bonding, depending on the lubricant and mixing conditions. I recommend studying compression force and lubrication time together with crospovidone level so that the formulation is evaluated under realistic manufacturing conditions.
Powder segregation is another important consideration, especially when the active ingredient and excipients differ significantly in particle size or density. Consistent blending, controlled transfer, and appropriate sampling are needed to determine whether the disintegrant is uniformly distributed. A laboratory result from a well-mixed small batch may not represent behavior during scale-up.
Compatibility should be assessed with the active pharmaceutical ingredient and the other excipients in the formulation. Useful development work may include accelerated compatibility studies, powder characterization, tablet disintegration, dissolution, friability, hardness, and stability evaluation. I would interpret each result in relation to the product target rather than treating one test, such as fast disintegration, as sufficient evidence of overall suitability.
When I evaluate a supplier, I look beyond the product name. The supplier should be able to explain the grade identity, provide a clear specification and batch CoA, describe packaging and storage conditions, and support technical questions about application and scale-up. Buyers should also confirm whether the material is manufactured under controls suitable for the intended pharmaceutical use and whether the documentation matches their internal quality requirements.
Supply continuity is equally important for commercial projects. I recommend checking standard pack sizes, minimum order quantities, sample availability, production lead time, export documentation, and the supplier’s approach to raw-material or process changes. These details can affect validation planning even when the excipient itself performs well in the laboratory.
At Yuking, I approach crospovidone XL-10 sourcing as a technical and supply-chain decision, not simply a price comparison. We can discuss your dosage form, target use level, process route, required documentation, packaging expectations, and destination-market requirements before recommending a practical quotation or sample evaluation path. Any specification, availability, or lead-time statement should be confirmed against the current batch and order conditions.
For an efficient inquiry, I suggest sharing the intended dosage form, approximate annual or trial quantity, target market, preferred packaging, and any required quality documents. This information allows us to respond with more relevant material and commercial details. Where the grade name may vary between suppliers, I can also help organize a side-by-side review of specification items rather than relying on equivalent naming alone.
Crospovidone XL-10 may be a suitable choice when you need a crosslinked, water-insoluble superdisintegrant for rapid breakup of an immediate-release tablet, capsule fill, or related solid oral dosage form. The correct decision depends on the interaction between the grade, active ingredient, excipient matrix, compression process, and finished-product requirements. I would begin with a controlled screening study, confirm the material specification, and compare performance against your dissolution and disintegration targets.
Your next step should be to define the dosage form, trial quantity, target performance, and documentation requirements before requesting a sample or quotation. Contact Yuking with those details for a focused discussion about crospovidone XL-10 supply, technical documentation, packaging, and export support. This process helps reduce avoidable sourcing risk while keeping the final formulation decision evidence-based.
For more crospovidone xl 10information, please contact us. We will provide professional answers.